Larson Financial Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40K Buy
619
+345
+126% +$24.3K ﹤0.01% 1465
2025
Q4
$18.4K Sell
274
-80
-23% -$5.38K ﹤0.01% 1768
2025
Q3
$26K Buy
354
+343
+3,118% +$22.8K ﹤0.01% 1489
2025
Q2
$572 Buy
11
+4
+57% +$228 ﹤0.01% 2824
2025
Q1
$447 Buy
7
+5
+250% +$290 ﹤0.01% 2606
2024
Q4
$96 Sell
2
-192
-99% -$9.85K ﹤0.01% 2608
2024
Q3
$11.1K Buy
194
+192
+9,600% +$11K ﹤0.01% 1441
2024
Q2
$105 Hold
2
﹤0.01% 2231
2024
Q1
$81 Hold
2
﹤0.01% 1720
2023
Q4
$74 Buy
+2
New +$75 ﹤0.01% 1732

Other funds holding HALO

Larson Financial Group's HALO Position: Q1 2026 in Review

Larson Financial Group increased its Halozyme (HALO) stake by 126% in Q1 2026, buying an estimated $24.3K and bringing the position to 619 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Larson Financial Group first reported a position in HALO in Q4 2023 and has held it in 10 quarters since. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Larson Financial Group held 619 shares of Halozyme worth $40K as of Q1 2026.
  • Larson Financial Group bought 345 Halozyme shares in Q1 2026, an estimated $24.3K.
  • Halozyme made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1465 holding.
  • Larson Financial Group first reported a position in Halozyme in Q4 2023 and has held it in 10 quarters since.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.